GB Sciences, Inc. (GBLX)
GB Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.00, up 33.33% on the session, giving a market capitalisation of $162,828. On trailing twelve-month figures it carries a trailing P/E of -0.10, a net margin of 0.0%. Its beta of 9.86 implies it has historically moved more than the broad market.
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
GB Sciences, Inc. is most often compared with the following Healthcare names: